Literature DB >> 12775682

Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut.

Jane Freeman1, Fiona J O'Neill, Mark H Wilcox.   

Abstract

Clostridium difficile is recognized as an important nosocomial pathogen. C. difficile infection (CDI) is thought to arise as a result of depletion of the normal gut flora by antimicrobial agents. Cefotaxime (CTX) is well-known for its propensity to cause CDI, but the reasons behind its particular predisposition to the disease remain unclear. Previous investigations have so far relied upon the hamster model of CDI or human volunteers. We have used a triple-stage chemostat model of the human gut to investigate the behaviour of C. difficile and components of the normal gut flora, in response to exposure to CTX alone, and in combination with its active metabolite desacetylcefotaxime (dCTX). C. difficile remained in a steady state during non-antibiotic exposed periods, with no detectable cytotoxin. During both antibiotic exposure regimens, proliferation of C. difficile and elevated cytotoxin levels were observed. Cessation of antibiotic instillation produced a reduction in cytotoxin levels and viable counts. Decreases in bacterial counts were observed in response to both antibiotic exposure regimens, notably for bifidobacteria and bacteroides. Numbers of bacteroides were profoundly affected by exposure to the CTX/dCTX combination, and this may indicate a possible role for bacteroides in colonization resistance. We believe that the gut model is a promising method for studying C. difficile pathogenesis in conditions analogous to the in vivo situation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12775682     DOI: 10.1093/jac/dkg267

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  29 in total

1.  Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice.

Authors:  Nicole J Pultz; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

2.  Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus.

Authors:  N J Asha; D Tompkins; M H Wilcox
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

Review 3.  Models for the study of Clostridium difficile infection.

Authors:  Emma L Best; Jane Freeman; Mark H Wilcox
Journal:  Gut Microbes       Date:  2012-03-01

4.  Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates.

Authors:  Thomas Akerlund; Bo Svenungsson; Asa Lagergren; Lars G Burman
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

5.  Characterization of the sporulation initiation pathway of Clostridium difficile and its role in toxin production.

Authors:  Sarah Underwood; Shuang Guan; Vinod Vijayasubhash; Simon D Baines; Luke Graham; Richard J Lewis; Mark H Wilcox; Keith Stephenson
Journal:  J Bacteriol       Date:  2009-09-25       Impact factor: 3.490

Review 6.  Hospital infections, animal models and alternatives.

Authors:  R Seabra; N Bhogal
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-12-19       Impact factor: 3.267

7.  Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection.

Authors:  Simon D Baines; Jane Freeman; Mark H Wilcox
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

8.  Epidemic Clostridium difficile strains demonstrate increased competitive fitness compared to nonepidemic isolates.

Authors:  Catherine D Robinson; Jennifer M Auchtung; James Collins; Robert A Britton
Journal:  Infect Immun       Date:  2014-04-14       Impact factor: 3.441

9.  Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.

Authors:  Katie Saxton; Simon D Baines; Jane Freeman; Rachael O'Connor; Mark H Wilcox
Journal:  Antimicrob Agents Chemother       Date:  2008-08-18       Impact factor: 5.191

10.  Antimicrobial drugs and community-acquired Clostridium difficile-associated disease, UK.

Authors:  J A Chris Delaney; Sandra Dial; Alan Barkun; Samy Suissa
Journal:  Emerg Infect Dis       Date:  2007-05       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.